A team of scientists in India has created a potentially game-changing coronavirus test.

Named “Feluda,” after the fictional Indian character equivalent to Sherlock Holmes, the new test for COVID-19 uses gene-editing technology to detect the virus, the BBC reported. Recently cleared for commercial use by India’s drug regulator, its creators see it as a cheap and speedy testing innovation.

The Feluda is the first paper-based coronavirus test to become available on the market. Similar to the nasal swab PCR (polymerase chain reaction) test, it will come in a kit which can be used at home and give results in less than an hour. It provides its findings on a piece of paper, with two blue lines denoting that the user has tested positive for the novel virus, and a single blue line indicating they are negative.

“We are trying for a simple, affordable, and truly point-of-care test so widespread testing is not limited by machines and manpower,” test co-developer Dr. Debojyoti Chakraborty told the UK outlet, touting Feluda’s ability to skip the often time-consuming lab processing portion which currently slows down many tests’ ability to offer fast results.

While similar to the relatively expensive but reliably accurate PCR swab tests, Feluda kits don’t rely on chemical amplification of the virus’ genetic material (which requires a lab), but CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology, which searches the tested person’s genes for a set of letters denoting the virus.

Feluda kits cost 500 rupees ($6.75) to the PCR test’s 2,400 rupees ($32.84). In a trial of 2,000 patients, researchers found that the test has a 96% accuracy rate for positive tests and a 98% accuracy rate for negative tests.

Scientists around the globe are hopeful the test will prove a valuable addition to India’s coronavirus response and potentially be adopted by other nations.

“India has the opportunity to show the value of this test, because it has such a big population and it’s coming right at the time when it is needed,” Harvard Medical School research fellow Dr. Stephen Kissler told the BBC. “If their efficacy is demonstrated, it can have benefits that ripple around the world.”

India currently has over 6.6 million coronavirus cases, the highest in the world after the US, which has 7.4 million, according to Johns Hopkins’ global coronavirus map.